-

Parnell Launches nixiFLOR® - First FDA-Approved Generic Florfenicol + Flunixin Combination for BRD

nixiFLOR® is the first FDA-approved generic version of Resflor Gold®, containing the same active ingredients, florfenicol and flunixin meglumine. The FDA determined the product is bioequivalent to Resflor Gold® for the treatment of bovine respiratory disease (BRD) and control of BRD-associated pyrexia (fever) in beef and non-lactating dairy cattle.

OVERLAND PARK, Kan.--(BUSINESS WIRE)--Parnell Technologies Pty. Ltd. announced the U.S. launch of nixiFLOR® (florfenicol and flunixin meglumine) injectable solution, recently approved by the U.S. Food and Drug Administration for the treatment of bovine respiratory disease (BRD) and control of BRD-associated pyrexia (fever) in beef and non-lactating dairy cattle.

First FDA-Approved Generic Version of Resflor Gold® for BRD.

Share

nixiFLOR® is the first FDA-approved generic version of Resflor Gold®, containing the same active ingredients, florfenicol and flunixin meglumine. The FDA determined the product is bioequivalent to Resflor Gold®, offering veterinarians and producers a cost-effective alternative with the same proven performance.

“At Parnell, we are committed to bringing high-quality, proven products to market with the reliability and pricing veterinarians and producers need,” said Pablo Lamberto, President of U.S. Operations. “nixiFLOR® delivers exactly that, competitive pricing and bioequivalent performance that cattle operations can depend on.”

nixiFLOR® combines antimicrobial treatment with anti-inflammatory action in a single subcutaneous injection, targeting BRD pathogens while reducing fever helping cattle recover quickly and remain on feed. Its single-dose administration supports operational efficiency by reducing labor and chute time.

“BRD remains one of the most significant challenges in cattle production,” said Justin Miller, VP of U.S. Commercial Operations. “nixiFLOR® provides a trusted dual-action solution that helps protect herd health while supporting producer profitability.”

As with all florfenicol-containing products, nixiFLOR® is available by prescription only and must be used under the direction of a licensed veterinarian.

About Parnell

Parnell is a global veterinary pharmaceutical company focused on developing, manufacturing and commercializing innovative animal health solutions for production and companion animals. Learn more at www.parnell.com.

@2026 Parnell Technologies Pty LTD. nixiFLOR® is a trademark of Parnell Technologies Pty LTD. Other product names are trademarks of their respective owners. MKT-26-066 PA US

Contacts

Media Contact:
Sue Hart
Associate Director Marketing & Sales Operations
sue.hart@parnell.com
715-790-8260

Industry:

Parnell

Release Versions
English

Contacts

Media Contact:
Sue Hart
Associate Director Marketing & Sales Operations
sue.hart@parnell.com
715-790-8260

Social Media Profiles
Parnell Livestock Facebook
Parnell LinkedIn
Parnell YouTube
More News From Parnell

Parnell Expands PropofolVet Multidose Offering with New 50 mL Presentation

OVERLAND PARK, Kan.--(BUSINESS WIRE)--Parnell today announced the availability of a new 50 mL presentation of PropofolVet Multidose (propofol injectable emulsion), providing veterinary professionals with an additional option to support anesthesia protocols while helping optimize inventory management and reduce waste. The new presentation complements the existing 20 mL offering, extending the reach of Parnell's first generic propofol injectable emulsion for dogs.PropofolVet Multidose is indicated...

Parnell Adds Sevoflurane to Its Growing Veterinary Anesthesia Portfolio

OVERLAND PARK, Kan.--(BUSINESS WIRE)--Parnell today announced the launch of Sevoflurane Inhalation Anesthetic, expanding its anesthesia portfolio to better support veterinary teams across the full procedural workflow. Indicated for the induction and maintenance of general anesthesia in dogs, the new offering provides clinics with a reliable, cost-effective inhalant anesthetic option from a company veterinary teams already rely on. The addition reinforces Parnell’s commitment to delivering confi...

Parnell Acquires Noble Pharma LLC, Expanding U.S. Manufacturing Capabilities

SYDNEY, Australia--(BUSINESS WIRE)--Parnell today announced the acquisition of Noble Pharma LLC, a U.S.-based pharmaceutical manufacturer, according to the Securities Purchase Agreement dated November 26, 2025. With this strategic acquisition, Parnell strengthens its U.S. operations and further advances its long-term commitment to delivering high‑quality products, reliable supply, and an enhanced level of support to its customers and distribution partners. Noble Pharma significantly enhances Pa...
Back to Newsroom